- Home
- ABEO
as of 04-06-2026 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 280.2M | IPO Year: | 2005 |
| Target Price: | $20.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.01 | EPS Growth: | 165.16 |
| 52 Week Low/High: | $3.93 - $7.54 | Next Earning Date: | 05-14-2026 |
| Revenue: | $2,998,000 | Revenue Growth: | 258.18% |
| Revenue Growth (this year): | 1276.65% | Revenue Growth (next year): | 112.53% |
| P/E Ratio: | 4.77 | Index: | N/A |
| Free Cash Flow: | -84301000.0 | FCF Growth: | N/A |
AI-Powered ABEO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
Chief Executive Officer
Avg Cost/Share
$4.38
Shares
29,985
Total Value
$131,481.23
Owned After
1,430,423
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.76
Shares
785
Total Value
$3,736.60
Owned After
567,775
SEC Form 4
Director
Avg Cost/Share
$5.09
Shares
2,000
Total Value
$10,181.20
Owned After
84,065
SEC Form 4
Director
Avg Cost/Share
$5.09
Shares
16,284
Total Value
$82,895.33
Owned After
63,456
SEC Form 4
Director
Avg Cost/Share
$5.09
Shares
18,065
Total Value
$91,961.69
Owned After
173,614
SEC Form 4
Director
Avg Cost/Share
$5.09
Shares
20,070
Total Value
$102,168.34
Owned After
137,722
SEC Form 4
Director
Avg Cost/Share
$5.09
Shares
14,814
Total Value
$75,412.15
Owned After
167,935
SEC Form 4
SVP, Chief Legal Officer
Avg Cost/Share
$5.33
Shares
13,578
Total Value
$72,382.96
Owned After
451,134
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$5.33
Shares
18,666
Total Value
$99,506.58
Owned After
567,775
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.33
Shares
69,832
Total Value
$372,267.41
Owned After
1,430,423
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | ABEO | Chief Executive Officer | Mar 31, 2026 | Sell | $4.38 | 29,985 | $131,481.23 | 1,430,423 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Mar 16, 2026 | Sell | $4.76 | 785 | $3,736.60 | 567,775 | |
| Alvino Mark | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 2,000 | $10,181.20 | 84,065 | |
| Crombez Eric | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 16,284 | $82,895.33 | 63,456 | |
| Alland Leila | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 18,065 | $91,961.69 | 173,614 | |
| Silverstein Christine Berni | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 20,070 | $102,168.34 | 137,722 | |
| Wuchterl Donald A. | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 14,814 | $75,412.15 | 167,935 | |
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Jan 22, 2026 | Sell | $5.33 | 13,578 | $72,382.96 | 451,134 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Jan 22, 2026 | Sell | $5.33 | 18,666 | $99,506.58 | 567,775 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Jan 22, 2026 | Sell | $5.33 | 69,832 | $372,267.41 | 1,430,423 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 17, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 17, 2026 · 100% conf.
1D
-2.92%
$4.81
Act: -4.41%
5D
-6.39%
$4.63
20D
-6.47%
$4.63
false 0000318306
0000318306
2026-03-17 2026-03-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 17, 2026
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 17, 2026, Abeona Therapeutics Inc. issued a press release regarding its financial results for the year ended December 31, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated March 17, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abeona Therapeutics Inc.
(Registrant)
By: /s/ Joseph Vazzano
Name: Joseph Vazzano
Title: Chief Financial Officer
Date: March 17, 2026
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
1D
-2.22%
$4.84
Act: -8.48%
5D
-5.29%
$4.69
Act: -15.15%
20D
-8.67%
$4.52
Act: +11.12%
false 0000318306
0000318306
2025-11-12 2025-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2025
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2025, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended September 30, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated November 12, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abeona Therapeutics Inc.
(Registrant)
By: /s/ Joseph Vazzano
Name: Joseph Vazzano
Title: Chief Financial Officer
Date: November 12, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
Q2 2025 Earnings
8-KAug 14, 2025
false 0000318306
0000318306
2025-08-14 2025-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 14, 2025
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2025, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended June 30, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated August 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abeona Therapeutics Inc.
(Registrant)
By: /s/ Joseph Vazzano
Name: Joseph Vazzano
Title: Chief Financial Officer
Date: August 14, 2025
Compare ABEO vs Leading Stocks
See how ABEO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.